Hormonal contraception and bone mineral density

References

• Sabatier JP, Guaydier-Souquieres G, Laroche D et al. Bone mineral acquisition during adolescence and early childhood: a study in 574 healthy females 10–24 years of age. Osteoporos. Int.6(2), 41–48 (1996).
   Google Scholar
• Cromer BA, Harel Z. Adolescents: at increased risk of osteoporosis? Clin. Pediatr. (Phila.)39(10), 565–574 (2000).
   PubMedGoogle Scholar
• Dempster DW. Bone remodeling. In: Osteoporosis. Etiology, Diagnosis, and management. Riggs BL, Melton LJ III (Eds). Lippincott–Raven, PA, USA, 67–91 (1995).
   Google Scholar
• Duursma SA, Raymakers JA, Boereboom FTJ et al. Estrogen and bone metabolism. Obstet. Gynecol. Survey47, 38–44 (1991).
   Google Scholar
• Hayes WC, Piazza SJ, Zysset PK. Biomechanics of fracture risk prediction of the hip and spine by quantitative computed tomography. Radiol. Clin. North Am.29(1), 1–18 (1991).
   PubMed Web of Science ®Google Scholar
• No authors listed. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser.843, 1–129 (1994).
   PubMed Web of Science ®Google Scholar
• Sowers MR, Galuska DA. Epidemiology of bone mass in premenopausal women. Epidemiol. Rev.15(2), 374–398 (1993).
   PubMedGoogle Scholar
• Castelo-Branco C, Vicente JJ, Pons F et al. Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. J. Reprod. Med.46(10), 875–879 (2001).
   PubMedGoogle Scholar
• Goldsmith NF, Johnston JO. Bone mineral effects of oral contraceptives, pregnancy and lactation. J. Bone Joint Surg.57(5), 657–668 (1975).
   PubMedGoogle Scholar
• Cooper C, Hannford P, Croft P et al. Oral contraceptive pill use and fractures in women: a prospective study. Bone14(1), 41–45 (1993).
   PubMed Web of Science ®Google Scholar
• Barad D, Koperberg C, Wactawsi-Wende J et al. Prior oral contraception and postmenopausal fracture: a Woman’s Health Initiative observational cohort study. Fertil. Steril.84(2), 374–383 (2005).
   PubMed Web of Science ®Google Scholar
• Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception57(4), 231–235 (1998).
   PubMed Web of Science ®Google Scholar
• Johansson C, Mellstrom D. An earlier fracture as a risk factor for new fracture and its association with smoking and menopausal age in women. Maturitas24(1–2), 97–106 (1996).
   PubMed Web of Science ®Google Scholar
• O’Neill TW, Marsden D, Adams JE et al. Risk factors, falls, and fracture of the distal forearm in Manchester, UK. J. Epidemiol. Comm. Health50(3), 288–292 (1996).
   PubMed Web of Science ®Google Scholar
• Tuppurainen M, Kröger H, Saarikoski S et al. The effect of previous oral contraceptive use on bone mineral density in perimenopausal women. Osteoporos. Int.4, 93–98 (1994).
   PubMedGoogle Scholar
• Michaelsson K, Baron JA, Farahmand BY et al. Oral contraceptive use and risk of hip fracture: a case–control study. Lancet353(9163), 1481–1484 (1999).
   PubMed Web of Science ®Google Scholar
• Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J. Clin. Endocrinol. Metab.95(11), 4909–4916 (2010).
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Oral contraceptive use and risk of fractures. Contraception73(6), 571–576 (2006).
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Tavani A, Gallus S. Oral contraceptives and risk of hip fractures. Lancet354(9175), 325–326 (1999).
   Google Scholar
• Lopez LM, Grimes DA, Schulz KF et al. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database System. Rev.2, CD006033 (2009).
   Google Scholar
• Mehta S. Bone loss, contraception and lactation. Acta Obstet. Gynecol. Scand.72(3), 148–156 (1993).
   PubMed Web of Science ®Google Scholar
• Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception73(5), 445–469 (2006).
   PubMed Web of Science ®Google Scholar
• Nappi C, Di Spiezie SA, Acunzo G et al. Effects of low-dose and ultra-low-dose combined oral contraceptives use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception67(5), 355–359 (2003).
   PubMed Web of Science ®Google Scholar
• Berenson AB, Radecki CM, Grady JJ et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet. Gynecol.98(4), 576–582 (2001).
   PubMed Web of Science ®Google Scholar
• Berenson AB, Breitkopf CR, Grady JJ et al. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet. Gynecol.103(5), 899–906 (2004).
   PubMed Web of Science ®Google Scholar
• Endrikat J, Mih E, Düsterberg B et al. A 3 year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20µg or 30µg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception69(3), 179–187 (2004).
   PubMed Web of Science ®Google Scholar
• Gargano V, Massaro M, Morra I et al. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception78(1), 10–15 (2008).
   PubMed Web of Science ®Google Scholar
• Berenson AB, Rahman M, Breitkopf CR et al. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet. Gynecol.112(4), 788–799 (2008).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Bonny AE, Stager M et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24 month prospective study. Fertil. Steril.90(6), 2060–2067 (2008).
   PubMed Web of Science ®Google Scholar
• Hartard M, Kleinmond C, Wiseman M et al. Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone40(2), 444–450 (2007).
   PubMed Web of Science ®Google Scholar
• Hartard M, Kleinmond C, Luppa P et al. Comparison of the skeletal effects of the progestogens desogestrel and levonorgestrel in oral contraceptive preparations in young women: controlled, open, partly randomized investigation over 13 cycles. Contraception74(5), 367–375 (2006).
   PubMed Web of Science ®Google Scholar
• Lara-Torre E, Edwards CP, Perlman SP et al. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J. Pediatr. Adolesc. Gynecol.17(1), 17–21 (2004).
   PubMedGoogle Scholar
• Cromer BA, Stager M, Bonny A et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J. Adolesc. Health35(6), 434–441 (2004).
   PubMed Web of Science ®Google Scholar
• Lloyd T, Petit MA, Lin HM et al. Lifestyle factors and the development of bone mass and bone strength in young women. J. Pediatr.144(6), 776–782 (2004).
   PubMed Web of Science ®Google Scholar
• Rome E, Ziegler J, Secic M et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J. Pediatr. Adolesc. Gynecol.17(6), 373–377 (2004).
   PubMedGoogle Scholar
• Tharnprisarn W, Taneepanichskul S. Bone mineral density in adolescent and young Thai girls receiving oral contraceptives compared with depot medroxyprogesterone acetate: a cross-sectional study in young Thai women. Contraception66(2), 101–103 (2002).
   PubMedGoogle Scholar
• Lloyd T, Taylor DS, Lin HM et al. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. Fertil. Steril.74(4), 734–738 (2000).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Blair J, Mahan JD et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgesterel (Norplant), or oral contraceptives. J. Pediatr.129(5), 671–676 (1996).
   PubMed Web of Science ®Google Scholar
• Polatti F, Perotti F, Felippa N et al. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception51(4), 221–224 (1995).
   PubMed Web of Science ®Google Scholar
• Scholes D, Ichikawa L, LaCroix AZ et al. Oral contraceptive use and bone density in adolescent and young adult women. Contraception81(1), 35–40 (2010).
   PubMed Web of Science ®Google Scholar
• Almstedt Shoepe H, Snow CM. Oral contraceptive use in young women is associated with lower bone mineral density than that of controls. Osteoporos. Int.16(12), 1538–1544 (2005).
   PubMed Web of Science ®Google Scholar
• Pikkarainen E, Lehtonen-Veromaa M, Mottonen T, Kautiainen H, Viikari J. Estrogen–progesttin contraceptive use during adolescence prevents bone mass acquisition: a 4 year follow-up study. Contraception78, 226–231 (2008).
   PubMed Web of Science ®Google Scholar
• Beksinska ME, Kleinschmidt I, Smit JA, Farley TM. Bone mineral density in young women aged 19–24 after 4–5 years of exclusive and mixed use of hormonal contraception. Contraception80(2), 128–132 (2009).
   PubMed Web of Science ®Google Scholar
• Beksinska ME, Kleinschmidt I, Smit JA, Farley TM. Bone mineral density in a cohort of adolescents during use of norethisterone emanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate. Contraception79, 345–349 (2009).
   PubMed Web of Science ®Google Scholar
• Masaryk P, Lunt M, Benevolenskaya L et al. Effects of menstrual history and use of medications on bone mineral density: the EVOS study. Calcif. Tissue Int.63(4), 271–276 (1998).
   PubMedGoogle Scholar
• Johnell O, Nilsson BE. Life-style and bone mineral mass in perimenopausal women. Calcif. Tissue Int.36(4), 354–356 (1984).
   PubMedGoogle Scholar
• Gambacciani M, Ciaponi M, Cappagli B et al. Longitudinal evaluation of perimenopausal femoral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Osteoporos. Int.11(6), 544–548 (2000).
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Cappagli B, Ciaponi M et al. Hormone replacement therapy in perimenopause: the effect of low dose oral contraceptive preparation on bone quantitative ultrasound characteristics. Menopause6(1), 43–48 (1999).
   PubMed Web of Science ®Google Scholar
• Volpe A, Amram A, Cagnacci A et al. Biochemical aspects of hormonal contraception: effects on bone metabolism. Eur. J. Contracept. Reprod. Health Care2(2), 123–126 (1997).
   PubMedGoogle Scholar
• Gambacciani M, Spinetti A, Cappagli B et al. Hormone replacement therapy in perimenopausal women with low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas19(2), 125–131 (1994).
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Spinetti A, Taponeco F et al. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet. Gynecol.83(3), 392–396 (1994).
   PubMed Web of Science ®Google Scholar
• Shargil AA. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int. J. Fertil.30, 18–28 (1985).
   PubMedGoogle Scholar
• Taechakraichana N, Limpaphayom K, Ninlagarn T et al. A randomized trial of oral contraceptive and hormone replacement therapy on bone mineral density and coronary heart disease risk factors in postmenopausal women. Obstet. Gynecol.95(1), 87–94 (2000).
   PubMedGoogle Scholar
• Von Kesseru E, Etchepareborda JJ, Wikinski R et al. Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns. Contraception61(5), 317–322 (2000).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Juliato CT, Villarreal M et al. Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives. Contraception74(3), 259–263 (2006).
   PubMed Web of Science ®Google Scholar
• Massaro M, Di Carlo C, Gargano V, Formisano C, Bifulco G, Nappi C. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. Contraception81, 209–214 (2010).
   PubMed Web of Science ®Google Scholar
• Massai R, Makarainen L, Kuukankorpi A, Kippling C, Duijkers I, Dieben T. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. Hum. Reprod.20, 2764–2768 (2005).
   PubMed Web of Science ®Google Scholar
• Mishell DR. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J. Reprod. Med.41(Suppl. 5), 381–390 (1996).
   PubMed Web of Science ®Google Scholar
• Oritz A, Hiroi F, Stanczyk FZ et al. Serum medroxyprogesterone acetate MPA concentration and ovarian function following intramuscular injection of depo-MPA. J. Clin. Endocrinol. Metab.44(1), 32–38 (1977).
   PubMedGoogle Scholar
• Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J. Reprod. Med.41(5 Suppl.), 407–413 (1996).
   PubMedGoogle Scholar
• Margulies R, Miller L. Increased depot medroxyprogesterone acetate use increases family planning program pharmaceutical supply costs. Contraception63(3), 147–149 (2001).
   PubMedGoogle Scholar
• Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception70, 269–275 (2004).
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2 year randomimized study of contraceptive efficacy and bone mineral density. Contraception80, 7 (2009).
   PubMed Web of Science ®Google Scholar
• Cundy T, Evans M, Roberts H et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ303(6793), 13–16 (1991).
   PubMed Web of Science ®Google Scholar
• Lappe JM, Kimmel DB, Stegman MR. Depo-medroxyprogesterone acetate contraception exposure and stress fractures in female military recruits. J. Bone Mine. Res.12(Suppl.), 173 (1997).
   Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception78(6), 459–464 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenburg L, Zhang Y, Constant D et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception76(6), 425–431 (2007).
   PubMedGoogle Scholar
• Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesterone acetate. Contraception73(6), 577–583 (2006).
   PubMed Web of Science ®Google Scholar
• Shaarawy M, El-Mallah S, Seoudi S et al. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception74(4), 297–302 (2006).
   PubMedGoogle Scholar
• Wanichsetakul P, Kamudhamas A, Watanaruanngkovit P et al. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception65(6), 407–410 (2002).
   PubMed Web of Science ®Google Scholar
• Ott SM, Scholes D, Lacroix AZ et al. Effects of contraceptive use on bone biochemical markers in young women. J. Clin. Endocrinol. Metab.86(1), 179–185 (2001).
   PubMed Web of Science ®Google Scholar
• Perrotti M, Bahamondes L, Petta C et al. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil. Steril.76(3), 469–473 (2001).
   PubMedGoogle Scholar
• Petitti DB, Piaggio G, Mehta S et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an International Population. Obstet. Gynecol.95(5), 736–744 (2000).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Perotti M, Castro S et al. Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil. Steril.71(5), 849–852 (1999).
   PubMedGoogle Scholar
• Tang OS, Tang G, Yip P et al. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception59(1), 25–29 (1999).
   PubMed Web of Science ®Google Scholar
• Scholes D, Lacroix AZ, Ott SM et al. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet. Gynecol.93(2), 233–238 (1999).
   PubMed Web of Science ®Google Scholar
• Cundy T, Cornish J, Roberts H et al. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet. Gynecol.92(4 Pt 1), 569–573 (1998).
   PubMed Web of Science ®Google Scholar
• Gbolade B, Ellis S, Murby B et al. Bone density in long-term users of depot medroxyprogesterone acetate. Br. J. Obstet. Gynecol.105(7), 790–794 (1998).
   PubMedGoogle Scholar
• Pavia LC, Pinto-Neto AM, Faundes A. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception58(6), 351–355 (1998).
   PubMedGoogle Scholar
• Taneepanichskul S, Intaraprasert S, Theppisai U et al. Bone mineral density during long-term treatment with Norplant® implants and depot medroxyprogestrone acetate. A cross-sectional study of Thai women. Contraception56(3), 153–155 (1997a).
   PubMed Web of Science ®Google Scholar
• Taneepanichskul S, Intaraprasert S, Theppisai U et al. Bone mineral density in long-term depot-medroxyprogesterone acetate acceptors. Contraception56(1), 1–3 (1997).
   PubMed Web of Science ®Google Scholar
• Virutamasen P, Wangsuphachart S, Reinprayoon D et al. Trabecular bone in long-term depot-medroxyprogesterone acetate users. Asia–Oceania. J. Obstet. Gynaecol.20(3), 269–274 (1994).
   PubMedGoogle Scholar
• Clark MK, Sowers MR, Levy B et al. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil. Steril.86(5), 1466–1474 (2006).
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Miller PD, Montgomery RV et al. Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception74(2), 90–99 (2006).
   PubMed Web of Science ®Google Scholar
• Clark MK, Sowers MR, Nichols S et al. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil. Steril.82(6), 1580–1586 (2004).
   PubMed Web of Science ®Google Scholar
• Naessen T, Olsson SE, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception52(1), 35–39 (1995).
   PubMed Web of Science ®Google Scholar
• Cundy T, Ames R, Horne A et al. A randomized controlled trial of oestrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J. Clin. Endocrinol. Metab.88(1), 78–81 (2003).
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Neff M, Keller PJ. A 2 year prospective study on the effects of depot medroxyprogesterone acetate on bone mass-response to oestrogen and calcium therapy in individual users. Contraception67(2), 79–86 (2003).
   PubMedGoogle Scholar
• Tang OS, Tang G, Yip PSF et al. Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density; a longitudinal cohort study. Contraception62(4), 161–164 (2000).
   PubMed Web of Science ®Google Scholar
• Cundy T, Cornish J, Evans MC et al. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ308(6923), 247–248 (1994).
   PubMed Web of Science ®Google Scholar
• Scholes D, LaCroix AZ, Ichikawa LE et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology13(5), 581–587 (2002).
   PubMed Web of Science ®Google Scholar
• Beksinska M, Kleinschmidt I, Smit J, Farley MM. Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate, or combined oral contraceptives for contraception. Contraception75(6), 438–443 (2007).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Lazebnik R, Rome E et al. Double-blinded randomized controlled trial of oestrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am. J. Obstet. Gynecol.192(1), 42–47 (2005).
   PubMedGoogle Scholar
• Scholes D, Lacroix AZ, Ichikawa LE et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch. Pediatr. Adolesc. Med.159(2), 139–144 (2005).
   PubMed Web of Science ®Google Scholar
• Scholes D, LaCroix AZ, Ichikawa LE et al. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception69(2), 99–104 (2004).
   PubMed Web of Science ®Google Scholar
• Busen NH, Britt RB, Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J. Adolesc. Health32(4), 257–259 (2003).
   PubMed Web of Science ®Google Scholar
• Harel Z, Johnson CC, Gold MA et al. Recovery of bone mimeral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception81(4), 281–291 (2010).
   PubMed Web of Science ®Google Scholar
• Walsh JS, Eastell R, Peel NF. Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density. Fertil. Steril.93(3), 697–701 (2008a).
   PubMedGoogle Scholar
• Beksinska M, Smit J, Kleinschmidt I, Farley T, Mbatha F. Bone mineral density in women aged 40–49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception71(3), 170–175 (2005).
   PubMed Web of Science ®Google Scholar
• Sanches L, Marchi NM, Castro S et al. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception78(5), 365–369 (2008).
   PubMedGoogle Scholar
• Orr-Walker BJ, Evans MC, Ames RW et al. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin. Endocrinol. (Oxf.)49(5), 615–618 (1998).
   PubMed Web of Science ®Google Scholar
• Cundy T, Cornish J, Roberts H et al. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am. J. Obstet. Gynecol.186(5), 978–983 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh JS, Eastell R, Peel NF. Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case–control study. J. Clin. Endocrinol. Metab.93(4), 1317–1323 (2008).
   PubMedGoogle Scholar
• Kaunitz AM, Arias R, McClung M et al. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception77(2), 67–76 (2008).
   PubMed Web of Science ®Google Scholar
• Monteiro-Dantas C, Espejo-Arce X, Lui-Filho JF et al. A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel- and levonorgestrel-releasing contraceptive implants. Reprod. Health12(4), 11 (2007).
   Google Scholar
• Bahamondes L, Monteiro-dantas C, Espejo-Arce X et al. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. Hum. Reprod.21(2), 466–470 (2006).
   PubMed Web of Science ®Google Scholar
• Vanderjagt DJ, Sagay AS, Imade GE et al. Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnover. Contraception72(3), 212–216 (2005).
   PubMed Web of Science ®Google Scholar
• Beerthuizen R, van Beek A, Massai R et al. Bone mineral density during long term use of the progestagen contraceptive implant Implanon compared with non-hormonal method of contraception. Hum. Reprod.15(1), 118–122 (2000).
   PubMed Web of Science ®Google Scholar
• Di X, Li Y, Zhang C et al. Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism. Contraception60(3), 161–166 (1999).
   PubMed Web of Science ®Google Scholar
• Diaz S, Reyes MV, Zepeda A et al. Norplant implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning. Hum. Reprod.14(10), 2499–2505 (1999).
   PubMed Web of Science ®Google Scholar
• Intaraprasert S, Taneepanichskul S, Theppisai U et al. Bone density in women receiving Norplant implants for contraception. J. Med. Assoc. Thai.80(11), 738–741 (1997).
   PubMedGoogle Scholar
• Caird LE, Reid-Thomas V, Hannan WJ et al. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin. Endocrinol. (Oxf.)41(6), 739–745 (1994).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Espejo-Arce X, Hildalgo MM et al. A cross-sectional study of the forearm bone density of users of long-term users of levonorgestrel-releasing intrauterine system. Hum. Reprod.21(5), 1316–1319 (2006b).
   PubMed Web of Science ®Google Scholar
• Curtis M, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception73, 470–487 (2006).
   PubMed Web of Science ®Google Scholar
• WHO. Medical Eligibilty Criteria for Contraceptive Use Third Edition. Department of Reproductive Health and Research, WHO, Geneva, Switzerland (2004).
   Google Scholar
• d’Arcangues C. WHO statement on hormonal contraception and bone health. Contraception73(5), 443–444 (2006).
   PubMed Web of Science ®Google Scholar
• Society for Adolescent Medicine. Depot medroxyprogesterone acetate and bone mineral density in adolescents – the black box warning: a position paper of the society for adolescent medicine. J. Adolesc. Health39(2), 296–301 (2006).
   PubMed Web of Science ®Google Scholar
• Duppe H, Gradsell P, Nilsson B et al. A single bone density measurement can predict fractures over 25 years. Calcif. Tissue Int.60(2), 171–174 (1997).
   PubMedGoogle Scholar
• Lewiecki EM, Gordon CM, Baim S et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone43(6), 1115–1121 (2007).
   Google Scholar
• Guilbert ER, Brown JP, Kaunitz et al. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception79(3), 167–177 (2009).
   PubMed Web of Science ®Google Scholar
• Westhoff C. Depot-medroxyprogesterone acetate injection Depo-Provera®: a highly effective contraceptive option with proven long-term safety. Contraception63(2), 75–87 (2003).
   Google Scholar